+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification

Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification

Human Pathology 41(11): 1617-1623

Adenoid cystic carcinoma of the breast is a rare subtype of breast cancer with basal-like features. Published studies on breast adenoid cystic carcinoma are limited, resulting in relatively scarce information on the value of predictive tumor markers. We studied 20 primary cases of adenoid cystic carcinoma of the breast for expression of estrogen receptor, progesterone receptor, androgen receptor, epidermal growth factor receptor, HER-2/neu, and topoisomerase IIα using immunohistochemistry and fluorescent in situ hybridization methods. Estrogen and progesterone receptor expression were detected in 1 case each. All tumors were uniformly negative for Her-2/neu expression. Androgen receptor and topoisomerase IIα expression were weakly positive in three cases and 7 cases, respectively. Epidermal growth factor receptor overexpression was detected in 13 cases (65% of all cases). Amplification of TOP2A or HER-2/neu gene was not detected in any of the cases. Our study shows that the majority of adenoid cystic carcinomas of the breast do not overexpress Her-2/neu, topoisomerase IIα, or estrogen receptor, and thus, they are unlikely to respond to therapies targeting these proteins. However, these tumors frequently over-express epidermal growth factor receptor, indicating a potential benefit from anti-epidermal growth factor receptor therapy for patients with advanced adenoid cystic carcinomas of the breast.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 051375856

Download citation: RISBibTeXText

PMID: 20688355

DOI: 10.1016/j.humpath.2010.04.013

Related references

Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification. Diagnostic Pathology 6: 108, 2012

EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Modern Pathology 18(8): 1027-1033, 2005

EGFR Intron 1 polymorphism in Asian Populations and its correlation with EGFR gene expression and amplification in breast tumor tissues. Cancer Biology and Therapy 5(11): 1445-1449, 2006

EGFR Intron 1 polymorphism in asian populations and its correlation with EGFR gene expression and amplification in breast tumour tissues. Cancer Biology & Therapy 5(11): 1445-1449, 2006

Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?. Journal of Clinical Pathology 58(7): 700-704, 2005

Human epidermal growth factor receptor 1 (EGFR) expression was not associated with gene amplification but intimately assoclated with HER2 gene amplification and protein expression in tissue microarray of clinical breast cancers. European Journal of Cancer Supplements 4(2): 122-123, 2006

Heterozygous mutation (G/G→G/A) at nt 2607 of the EGFR gene is closely associated with increases in EGFR copy number and mRNA half life, but impaired EGFR protein synthesis in squamous cell carcinomas of the head and neck - implication for gefitinib efficacy. Oncology Letters 1(6): 1017-1020, 2010

EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast. Korean Journal of Pathology 47(2): 107-115, 2013

Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast Cancer Research 10(3): R49, 2008

Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression. Oncology Reports 14(2): 337-343, 2005

Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. International Journal of Cancer 98(3): 398-408, 2002

Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer. Breast Cancer 21(1): 66-74, 2014

EGFR protein expression and gene amplification in squamous intraepithelial lesions and squamous cell carcinomas of the cervix. International Journal of Clinical and Experimental Pathology 7(2): 733-741, 2014

Mutation analysis of the EGFR pathway genes, EGFR, RAS, PIK3CA, BRAF, and AKT1 , in salivary gland adenoid cystic carcinoma. Oncotarget 9(24): 17043-17055, 2018

Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas. Neoplasma 59(5): 508-515, 2012